На главную
Результаты поиска “Pharmaceutical cost control generic drugs” за 2011
Conversation about drug pricing | Health care system | Heatlh & Medicine | Khan Academy
Dr. Laurence Baker talks to Sal about how drug prices are set. Created by Sal Khan. Watch the next lesson: https://www.khanacademy.org/science/health-and-medicine/health-care-system/v/health-care-costs-in-us-vs-europe?utm_source=YT&utm_medium=Desc&utm_campaign=healthandmedicine Missed the previous lesson? https://www.khanacademy.org/science/health-and-medicine/health-care-system/v/blue-cross-and-blue-shield?utm_source=YT&utm_medium=Desc&utm_campaign=healthandmedicine Health & Medicine on Khan Academy: No organ quite symbolizes love like the heart. One reason may be that your heart helps you live, by moving ~5 liters (1.3 gallons) of blood through almost 100,000 kilometers (62,000 miles) of blood vessels every single minute! It has to do this all day, everyday, without ever taking a vacation! Now that is true love. Learn about how the heart works, how blood flows through the heart, where the blood goes after it leaves the heart, and what your heart is doing when it makes the sound “Lub Dub.” About Khan Academy: Khan Academy is a nonprofit with a mission to provide a free, world-class education for anyone, anywhere. We believe learners of all ages should have unlimited access to free educational content they can master at their own pace. We use intelligent software, deep data analytics and intuitive user interfaces to help students and teachers around the world. Our resources cover preschool through early college education, including math, biology, chemistry, physics, economics, finance, history, grammar and more. We offer free personalized SAT test prep in partnership with the test developer, the College Board. Khan Academy has been translated into dozens of languages, and 100 million people use our platform worldwide every year. For more information, visit www.khanacademy.org, join us on Facebook or follow us on Twitter at @khanacademy. And remember, you can learn anything. For free. For everyone. Forever. #YouCanLearnAnything Subscribe to Khan Academy’s Health & Medicine channel: https://www.youtube.com/channel/UC1RAowgA3q8Gl7exSWJuDEw?sub_confirmation=1 Subscribe to Khan Academy: https://www.youtube.com/subscription_center?add_user=khanacademy
Просмотров: 53614 Khan Academy
Development and Delivery of Pharmaceutical Products  (CMC) - MaRS Best Practices
Moving from drug discovery to drug development requires a particular skillset usually not yet honed by start-ups. This phase of the development process is highly regulated and critical. Let Dr. Colin Minchom take you through the aspects of the Chemistry, Manufacturing and Control (CMC) portion of the drug development process. Watch this video to learn about the pharmaceutical product development which includes objectives of formulation, cost-effective strategies to reach key milestones and more. MaRS -- Building Canada's next generation of global technology companies. marsdd.com
Просмотров: 27471 MaRS Entrepreneurship Programs
Prescription Drug Costs Going Up
The price of prescription drugs is skyrocketing. According to the U.S. Government Accountability Office, last year, the price index for the top 100 commonly used drugs has gone up 6.6 percent over the past five years.
Просмотров: 331 FOX 2 St. Louis
The Future Of Generics
Mylan President, Heather Bresch, says the generic drug market will continue to be a winner.
Просмотров: 2411 Forbes
What if: A sliding scale were used to reimburse generic drugs to effectively drive down prices?
The policy option presented here was chosen to stimulate discussion, but is only one of several options examined by the author in the report "Managing Pharmaceutical Expenditure: An Overview and Options for Canada". Presenter and author: Aidan Hollis, Department of Economics, University of Calgary This is one in a series that puts forward tangible policy options for addressing the sustainability of Canada's healthcare. The series presents possibilities and opportunities for improving efficiency and providing additional revenue. On July 10, 2011, these options were presented to an international audience gathered in Toronto for the annual iHEA conference. They were selected by the presenters themselves, who are also authors of knowledge syntheses about healthcare financing that were commissioned by CHSRF (many other options are presented in their syntheses, which you will also find here). More at www.chsrf.ca
Просмотров: 663 CHSRF Legacy
Pharmocracy - How Much are Americans Overpaying for Prescription Drugs?
http://lef.org/pharmocracy This eye-opening video exposes the inefficient and corrupt reasons why medical prices have skyrocketed out of control. More important, it provides a blueprint for what citizens can do to combat the regulatory stranglehold over health care that enables the medical establishment to defraud consumers out of their health and money.
Просмотров: 361 Life Extension
Phases of Pharmaceutical Industry
The video-clip 'Phases of pharmaceutical industry' presents, step by step, the medicine line production. A 2D animation presents both the individual phases and the overall picture of the process. The students familiarize with the requirements and the conditions of medicine production, the required technology and the importance of health and safety specifications. What follows is the acquaintance with the methods of product qualitative control, the role of the head pf production and issues of waste management. The clip is instructional as far as medicine production is concerned and can be used as an introduction to the topic 'Industries' and 'Pharmacy'.
Просмотров: 189161 EducationalTVGreece
Policy options to control drug spending
As part of the Canadian Health Services Research Foundation's stakeholder event series, University of Toronto professor, Paul Grootendorst presented his new report, co-authored with Aidan Hollis, to healthcare leaders in Ottawa on February 18, 2011. Listen to the talk about the state of drug spending in Canada and possible policy options that may both contain costs and encourage innovation.
Просмотров: 435 CHSRF Legacy
Researcher on Call: Innovation and pharmaceutical spending
Spending on pharmaceuticals is a fast-growing component of overall healthcare spending in Canada. How can we manage drug spending while encouraging innovation in pharmaceutical technologies? Share your views on proposed policy options! On February 18, 2011, a small group of invited stakeholders met to discuss policy options for managing brand name and generic drug pricing, while encouraging innovation. On March 31, 2011, Researcher on Call expanded the discussion to include policy-makers, stakeholders, researchers and citizens across the country as Paul Grootendorst of the University of Toronto presents the recommendations of an expert paper he coauthored with Aidan Hollis of the University of Calgary. Speakers Paul Grootendorst and Bob Nakagawa propose realistic policy options for Canada!
Просмотров: 412 CHSRF Legacy
The economics of drugs
As part of the Canadian Health Services Research Foundation's stakeholder event series, University of Calgary professor, Aidan Hollis, presented to healthcare leaders in Ottawa on February 18, 2011. Listen to his discussion of the implications of policies around generic pricing, pharmacies, and competition, and possible roles for government to play in improvements.
Просмотров: 406 CHSRF Legacy
What if: The entry of new pharmaceuticals was managed?
What if: The entry of new pharmaceuticals was managed and their prices were negotiated based on value for the country as a whole, by using existing health technology assessment capacity? The policy option presented here was chosen to stimulate discussion, but is only one of several options examined by the author in the report "Value-Based Pricing of Pharmaceuticals in Canada: Opportunities to Expand the Role of Health Technology Assessment" Presenter and author: Chris G. Cameron, Canadian Agency for Drugs and Technologies in Health (CADTH) This is one in a series that puts forward tangible policy options for addressing the sustainability of Canada's healthcare. The series presents possibilities and opportunities for improving efficiency and providing additional revenue. On July 10, 2011, these options were presented to an international audience gathered in Toronto for the annual iHEA conference. They were selected by the presenters themselves, who are also authors of knowledge syntheses about healthcare financing that were commissioned by CHSRF (many other options are presented in their syntheses, which you will also find here). More at www.chsrf.ca
Просмотров: 753 CHSRF Legacy
Pharmocracy -  The Only Solution to the Healthcare Crisis
This eye-opening video exposes the inefficient and corrupt reasons why medical prices have skyrocketed out of control. More important, it provides a blueprint for what citizens can do to combat the regulatory stranglehold over health care that enables the medical establishment to defraud consumers out of their health and money.
Просмотров: 341 Life Extension
Strategic Joint Ventures & learn why your profits are being
http://www.miniploy.com Outsorcing To Make Money declan@leisuretime-media.comStrategic Joint Ventures & learn why your profits are being held to ransomMy aim is to increase the somewhat limited vision that some companies have to see the wealth of opportunities available to them through strategic alliances and joint ventures. The reason most companies don't do this is because of the significant costs and time involved in diverting resources to research and development new products. Most companies have established a high level of trust and credibility with their customers but rarely it to their full advantage. When a company has reached "business maturity" they are very powerful yet often underutilized assets. By that I mean having a balance of solid products and loyal customers, they have the finances to operate efficiently and effectively as well as the proper staff to carry out the daily operations. By being granted use and control of these assets a business development specialist like myself has the ability to locate and exploit profit centres that were previously untapped. You see, a mature business with a great list is actually a distribution network capable of selling dozens of additional products and services to their customers resulting in massive profits. After all, who doesn't want more profit that's so easy to come by! My experience allows me to match a variety of proven products or services to a list that will bring in massive profits for both parties.
Просмотров: 11 learnseoquick
Introducing GensourceRx - Authorized Pharmaceuticals Distributor
Gen-SourceRx, incorporated in 2001, provides powerful distribution & pharmacy marketing programs, backed by our Management's vast experience, vision & innovation in the Pharmaceuticals & Distribution industry. As an Authorized Distributor for 50 Major Generic Pharmaceutical Manufacturers, we strive to achieve the pinnacle in product & price integrity, offering competitive pricing to our customers that will ensure growth & longevity for the Future. Gen-SourceRx, accredited by VAWD, promotes "best practice" methodologies & operates under the highest standards set by the Wholesale Distribution Industry - National Association of Boards of Pharmacy.
Просмотров: 1230 gensourcerx
Month in Focus: "Europe! Hands Off Our Medicine" Campaign
Europe is the driving force behind a number of different moves that risk blocking access to life-saving, affordable generic medicines for patients in developing countries. MSF relies on these medicines to carry out its humanitarian work with some of the world's most vulnerable people. Millions more in developing countries depend on these medicines to stay alive and healthy. Learn more about the implications for access to medicines over trade talks between India and the European Union. To learn more about MSF's "Hands off" Campaign, visit msfaccess.org/​main/​access-patents/​hands-off-our-medicine-campaign/
Просмотров: 265 Doctors Without Borders / MSF-USA
Health Care Inform: Simple Solutions to America's Overspending & Overmedicating
Health Care Inform is merely an idea & we need your help to make it happen. 1. Share on Facebook 2. Visit our website www.healthcareinform.org 3. "Like" it here on YouTube and on Facebook Are you concerned about deficit spending, the rising cost of healthcare or the overuse of prescription drugs? The time has come for the safer, cheaper drugs and remedies to have a voice! Health Care Inform is an innovative plan for a public health education campaign to promote inexpensive over-the counter medicines, generic prescription drugs, natural remedies and healthy lifestyles. Drug companies are successfully marketing the latest fashionable drugs (which are marginally safe and questionably effective), while the "tried and true" alternatives, which have been proven safe for decades, have no voice because of their low profit status. In a time of extensive deficit spending, there are millions of dollars to be saved (not to mention lives). Physicians and patients can be re-educated three ways: 1) by "reps" who visit doctors' offices 2) by publishing resources 3) by public service announcements.
Просмотров: 492 Pepperberries
New oxycontin more difficult to abuse?
For months, one of the most abused prescription drugs has been replaced by a new formulation, making it more difficult to abuse, but it may also be less effective for patients who need it the most.
Просмотров: 48067 ABC15 Arizona
A true miracle- How I got rid of my acne. Daily skin-care routine.
Purchase the exact kit mentioned in video here: http://go.magik.ly/r/mamichula/d629/ (NOT SPONSORED) So the acne.org system worked great for my sister, Melanie...however I was not so lucky!!! :( Instead ACCUTANE is the only thing that cured me!!! See my youtube journery here: https://www.youtube.com/playlist?list=PLpGx5fmf3u7A5ncuWX85OAiziiE8XxzJw I FINALLY GOT A P.O. BOX!!!! MamiChula8153 (Lee) P.O. Box 154 East Islip, New York 11730-0154 Please send me letters, postcards, pictures!!! I don't want any of you spending your hard earned money on me. I would love to get to know about YOU! Whether you just want to reach out, need advice, have questions...this is a very special way for me to connect with my viewers. Please specify on envelope if I can read on air or if you would prefer for me to keep it private! CANT WAIT TO HEAR FROM YOUUUUU!!!!!!! :) XOXO! Follow me on Instagram & Facebook!! Instagram: Official_MamiChula Facebook.com/MamiChula8153FanPage This video is in NO way sponsored. I am not being payed/compensated for my review, and I am no affiliated with any brands mentioned. I am not a dermatologist, what worked for my skin may not work for others, but if you ask me- it is definitely worth a try. HOW I GOT RID OF ACNE SCARRING AT HOME (With Before & After Pics!!) http://youtu.be/3YHpnj5iSpk I decided to film this video so I could help anyone out there that is going through what I have been through. Intense acne can truly take an emotional toll on a person, this skin care system has changed my life. TAGS how i cured my acne how to at home skin care remedy system acne.org zits pimples blemishes scars sensitive oily oilyness treatment cure miracle benzoyl peroxide cleanser treatment moisturizer flakey dry acne prone large pores redness hyperpigmentation for men women teens natural easy hormones accutane differin nutrition ugly nasty embarrased hide helpful tips dealing with clean clear blackheads whiteheads dermatologist laser complexion positive "Acne Vulgaris" health beauty diet food cosmetics hiding hide camoflauge treat heal long term makeup
Просмотров: 13720700 MamiChula8153
Drug Shortages in America
WASHINGTON -- U.S. Senator Orrin Hatch (R-Utah), Ranking Member of the Senate Finance Committee, delivered the following opening statement at a committee hearing examining the impact of drug shortages in America: Chairman Baucus, thank you for convening today's hearing on such an important issue affecting our nation's patients and caregivers. We have all seen the disturbing stories in the press over the past several months about doctors unable to access critical medical products for their patients, and the impact that these drug shortages have had on patient care. While there is no doubt that increased attention and coordination has occurred between manufacturers and the government to begin addressing this problem, clearly more can be done to mitigate these shortages in the future. Drug supply shortages are not new. Any product that involves complex manufacturing and distribution could face some supply challenges. What is new is the volume of shortages, the importance of the therapies that are experiencing shortages, and the challenges these shortages present to patients and caregivers. Every year since 2005, drug shortages have become more prevalent and widespread. In 2009, there were 157 products on the FDA's shortage list, and in 2010 that number increased to 178. According to the University of Utah, which keeps track of shortages for the American Society of Health System Pharmacists, the total number of drugs in shortage currently exceeds 275 FDA- approved therapies and continues to grow. What is the impact of these increasing shortages? This crisis means worse outcomes for our patients, increased costs for caregivers and the government, slower medical advancement, and a persistent undermining of confidence in our country's healthcare system. Many of these drugs in shortage are used in current oncology treatment regimens. Not only are drug shortages impacting current treatments, they are harming future patients by delaying clinical trial results, increasing the length of clinical trials, and raising costs for research organizations. Our federal payer system is also bearing the cost of drug shortages. Clinicians are forced to scramble to find alternative treatment options for vulnerable patients, often at a much higher price for both the patient and the government. According to research by Premier, drug shortages could cost U.S. hospitals at least $415 million annually. This is because more expensive substitutes are often needed, intermediaries significantly mark up the price of these drugs, and there are additional labor costs associated with finding these alternative solutions. So what is causing this crisis? While this is clearly a complex issue, I believe we must look at the impact of federal programs on the generic injectable market. Seventy-four percent of drug shortages involved sterile injectables in 2010. I do not believe it is simply a coincidence that shortages are disproportionately impacting products with highly complex manufacturing processes that are also some of the lowest priced therapies. And I am not the only one to think that economic incentives play an important role in this issue. As recently highlighted in an article in the New England Journal of Medicine, experts contend that federal government pricing and rebate programs are a significant contributing factor to the current drug shortage crisis. The article also notes that there is an "untapped capacity" to produce generics but indicates that incentives to attract new entrants would be required to create redundancy in the market. Mr. Chairman I ask unanimous consent that this article be included in the record. Current pricing structures have been very effective at driving generic utilization. However, they may not fully capture or reward the costs associated with the complex development and manufacturing of injectables, as opposed to the more straightforward manufacturing process in the pill market. The current situation is simply unacceptable, and we must act to address this growing crisis. As most of my colleagues know, I am working on a solution that will continue to improve coordination between manufacturers and the government, but that also addresses some of the federal price control and rebate structures that prevent the true costs of bringing these important medicines to patients from being adequately addressed. I urge my colleagues to join me in working to solve this problem in the very near future. Senator Baucus, thank you again for convening this hearing today. I look forward to hearing from our witnesses and having a serious discussion about the steps we must take to address this crisis.
Просмотров: 337 SenatorOrrinHatch
re: The 1200% Increase in my Prescription Drug Costs
VYou:  http://vyou.com/tdcmoncton Facebook: tdcmoncton Twitter: tdcmoncton http://dailybooth.com/tdcmoncton/ Blogtv: http://www.blogtv.com/People/tdcmoncton Questions: http://www.formspring.me/tdcmoncton CanAmFun channel: http://www.youtube.com/user/canamfun http://www.stickam.com/member/tdcmoncton
Просмотров: 360 Cigare&Whiskey
Easier to Attack the Weak than the Wealthy
Rob Johnson: For GOP and Dems easier to make people pay for crisis than confront big campaign funders
Просмотров: 3816 TheRealNews
A Different Kind of Drug Dealer
Chris Johnson's MedSavers pharmacy helps uninsured patients access affordable medications.
Просмотров: 2563 McCombs School of Business
Esomeprazole (Nexium)
http://acidrefluxsorethroat.org/ Don't suffer from acid reflux in your throat anymore!
Просмотров: 3834 MalloryMckinney
Mylan announces Earnings
Heather Bresch, President of the pharmaceutical giant, on their recent announcement.
Просмотров: 1195 Forbes
Elizabeth Warren pHARMa infobomb
I gave Elizabeth Warren a stack of articles about fraud and harm inflicted by psychiatry.
Просмотров: 400 survivor030406
Lack of Drugs Puts Ukraine's HIV Patients at Risk
For more news and videos visit ☛ http://english.ntdtv.com or Follow us on Twitter ☛ http://twitter.com/NTDTelevision Twenty-thousand HIV-positive patients in Ukraine may die if the Ukraine government does not buy necessary drugs. Five of the 17 drugs required by these patients are in short supply and doctors say interrupting treatment or substituting other drugs could have devastating consequences. More from our correspondent in Kyiv. 20,000 HIV-positive patients may die in Ukraine, due to a lack of medications and treatment. Of the 17 drugs required by these patients, Ukraine is now short of at least five. Ukraine's National HIV Support Network says that the Ministry of Health has delayed buying necessary medication. [Sergey Dmitriev, Ukrainian HIV Support Network]: "One man may soon die soon. One man will soon be in a serious situation -- he already has tuberculosis or pneumonia and he was denied treatment because there were no drugs." Doctors say that fifty percent of people infected with HIV could die within a year if they don't receive timely treatment. The Ministry of Health has acknowledged that some drugs are missing. According to an official statement, they say that patients are being given similar drugs. [Sergey Dmitriev, Ukrainian HIV Support Network]: "This is unacceptable under any circumstance. These are high-precision drugs -- it is not aspirin, it is not an anesthetic -- and the amount of drug that needs to be taken depends on body weight." However, the greatest danger in substituting drugs is that the virus in a patient may develop a resistance to the drug, making the treatment ineffective. Doctors in Ukraine do not routinely conduct resistance tests for each patient to check what drugs may be ineffective. [Sergey Dmitriev, Ukrainian HIV Support Network]: "Ukraine could become exposed to a certain virus, as a result of resistance, for which there are no treatment options." The delay in providing drugs also means that treatment could be completely stopped for a few days, which could lead to disastrous consequences. [Tatiana Stepchenkova, Physician-Virologist]: "Can you imagine -- we have kept the virus under control and not let it breed and suddenly we have removed this control. The virus multiplies like crazy, like an avalanche. And the person ends up with all indications of the immune system failing. It's exactly the same as a death sentence." The Ministry of Health is confident there is no threat of interrupted treatment. They say some of the drugs are currently undergoing quality control, and any missing drugs will be procured by next week. Ukraine has the biggest number of HIV-positive patients in Europe -- between 170 to 360 thousand people live with the virus. Every day, 50 Ukrainians die from diseases caused by AIDS. NTD, Kyiv, Ukraine.
Просмотров: 256 NTDTV
Acne medication Ro-accutane linked to medical student's suicide
A father's account of his medical student son's suicide he believes was caused by adverse reaction to acne drug Ro-accutane / isotretinoin. Generic versions of this drug include: Sotret, Claravis, Amnesteem. Roche have withdrawn Roaccutane/Accutane from sale and they deny this withdrawal is linked to costly litigation in the US, due to Inflammatory Bowel Disease believed to be caused by isotretinoin. This video and other personal accounts together with talks by Professor David Healy, Professor Heather Ashton, Dr Andrew Herxheimer at our conference can be viewed at http://vimeo.com/user1816628/videos In this video, Jon Medland, who bravely agreed to be interviewed at the APRIL charity conference in 2008, gives his moving account of the sequence of events, following his son's decision to take Roaccutane to deal with moderate acne on his back, is just one example of a suicide linked to adverse reaction (ADR) probably triggered by medication. In a recent review of Yellow Card reports of ADRs by patients overseen by Professor Anthony Avery of Nottingham University and 5 other universities, for which I was Chair of the Advisory Group: Reports of suicidal thoughts was the 11th most commonly reported adverse reaction, almost as common as reports of rashes reported as linked to several different medications. I recently attended the inquest of a young woman who has been prescribed Roaccuate plus Dianette (Diane-35) and Prozac (fluoxetine) and Zopiclone a sleeping pill. All drugs linked to side effects of suicidal thoughts, actions and completed suicide. The Coroner only focussed on one drug and chose to ignore the others, probably because he unaware to the risks of each one of the four drugs, let alone the lethal combination of taking them all together. There are shortly to be inquests for young women who took their own lives, one in Australia who's suicide was linked to Dianette also known as Diane-35 or cyproterone-acetate and ethinylestradiol. The other in the UK linked to psychiatric drugs given following a trip abroad when the young woman used anti-malaria drug Malarone. All antimalarials are linked to psychiatric ADRs. Read more about this problem on www.april.org.uk and join with APRIL in a campaign to include ' Medication induced suicide' in the Suicide Prevention Strategy for England which has excluded this cause of suicide since its inception. The email address to contact the Department of Health in Whitehall office dealing with the revised strategy is on the Home Page of www.april.org.uk More video films from our conference may be viewed at http://vimeo.com/user1816628/videos Please contact APRIL if you think you, a friend or family member have had a psychiatric ADR. info at april dot org dot uk
Просмотров: 2543 APRIL charity
Deceptive Advertising Ruining VT Brand, Say Florists
Ordering flowers online is easy but costly and deceptive. Watch the video to find out more.
Просмотров: 186 MyNBC5-WPTZ
Просмотров: 1212 Tv1
Animated Trial Exhibits: Hatch Waxman ANDA Timeline
For more information, refer to our blog post on timeline trial exhibits: http://www.a2lc.com/blog/bid/34757/Litigation-Graphics-Timelines-Can-Persuade-Judges-and-Juries Timelines are used in virtually every piece of litigation. The same is true for PowerPoint timelines such as this exhibit. However, just because a timeline is a routine part of a courtroom proceeding, it does not mean that the chart itself must follow the typical colored date bar down the center with text bubbles placed around it. In this timeline, the colored bars represent periods of conversation with the FDA that delayed the approval of an ANDA. This visually proves that the citizen petition did not cause a delay in the approval of the generic version drug. Rather, it was the FDA taking its time in its review. Consider all of the information (thousands of pages of documents) that are summarzed in this timeline and the fact that it helped lead to a 100% defense verdict for Animators at Law's brand name pharmaceutical client.
Просмотров: 986 AnimatorsatLaw
16. Evolution of Tobacco Law
Environmental Politics and Law (EVST 255) This lecture continues the previous class's discussion of tobacco law. In this class, Professor Wargo highlights the unique issues of freedom of choice and freedom of speech that tobacco regulation create, as tobacco regulation restricts individual choice and corporate freedom of speech via advertising restrictions. Tobacco law also illustrates the difficulties of managing environmental hazards in the face of an industry with the resources to fund its own research and to fight regulation at every step of the process. The passing of the Family Smoking Prevention and Tobacco Control Act in 2009 is held up as a success story in tobacco regulation, as it places stricter standards on tobacco corporations. 00:00 - Chapter 1. Efforts on the Part of the Industry to Understand Nicotine 11:07 - Chapter 2. Tobacco Industry Challenges FDA; Various Settlements 20:24 - Chapter 3. If It's a Drug, Where's the Benefit? 25:25 - Chapter 4. Family Smoking Prevention and Tobacco Control Act 31:12 - Chapter 5. Control Programs; Mass Media; Science and Industry 37:09 - Chapter 6. Industry Arguments; Environmental and Consumer Group Arguments Complete course materials are available at the Open Yale Courses website: http://open.yale.edu/courses This course was recorded in Spring 2010.
Просмотров: 4682 YaleCourses
The Human Genome at 10: An Overview - Eric Lander
February 11, 2011 - A Decade with the Human Genome Sequence: Charting a Course for Genomic Medicine. More: http://www.genome.gov/27542738
Просмотров: 9881 National Human Genome Research Institute
Health Care Reform and Its Impact on Innovation in the Biopharmaceutical Industry (Kevin Sharer)
Visit USC on YouTube: https://www.youtube.com/user/USC/ Learn more about the University of Southern California: https://www.usc.edu The USC Schaeffer Center for Health Policy and Economics hosted a conference Oct. 22, 2010, titled, "Health Reform and the Economy: Are They Good for Each Other?" Conference panels examined critical reform issues related to reducing costs, improving quality, ensuring innovation and changing health care delivery. The assembly of renowned speakers from government, academia and industry presented different views -- some were concerned that health reform will not control costs, while others believed that incentives in the new health law for more robust information technology and provider payment reform will begin to bend the cost curve. In the panel titled "New Rules: Will They Chill Innovation?" panelists Darius Lakdawalla, Daniel McFadden, Kevin Sharer (presentation: "Health Care Reform and Its Impact on Innovation in the Biopharmaceutical Industry") and Micah Weinberg explored whether health reform will reduce market incentives for pharma and device makers to develop new technology due to potential impacts on profits. It was acknowledged that technology is a major cost driver but also that higher prices support innovation that benefits future patients. In addition, opportunities remain because of unmet need, an aging population, the fact that innovation is valued and global markets. Learn more about the University of Southern California: http://www.usc.edu Learn more about the USC Schaeffer Center for Health Policy and Economics: http://healthpolicy.usc.edu/
Просмотров: 249 USC
Eric Roberts visits popular Los Angeles news show to discuss Genmed
Eric Roberts, the new spokesman for Genmed Holding Corporation, visits the set of KCAL 9 News at Noon to discuss the company and its mission to distribute low cost generic drugs into the global market of countries in need
Просмотров: 462 scriptedconsulting
Money Talks: Profits Before Patient Safety (full film)
Просмотров: 16394 HollyM
Mylan Inc Topped Q3 Results, Top Line Up 16.2% YoY
Mylan Inc (NYSE:MYL) reported Q3 EPS of $0.55, ahead of consensus estimates of $0.51 per share. Revenues for the quarter rose 16.2% year-over-year to $1.58 billion, topping consensus estimates of $1.54 billion. The company sees 2011 EPS of $1.98 to $2.02, vs. consensus estimates of $2.00 per share. Mylan Chairman and CEO Robert J. Coury said: "We have once again delivered a quarter of strong top-line and bottom-line growth, a continued testament to the scale and diversity of our powerful global platform. I would like to note in particular the very impressive results of our specialty segment, Dey Pharma. As a result of strong execution across this business, Dey's performance is accelerating and it continues to be an important and exciting asset and growth driver for Mylan--one which we will continue to build on in the future." Mylan has potential upside of 38.1% based on a current price of $18.21 and an average consensus analyst price target of $25.14.
Просмотров: 188 FinancialNewsOnline
Richard Scheller: Developing Products that Save Lives [Entire Talk]
As Genentech's Executive Vice President of Research and Early Development, Richard Scheller leads scientists discovering medicines that will significantly impact the lives of patients. In this candid interview, he describes the challenges of his industry, and outlines the required steps for developing products in a heavily regulated environment. Scheller also shares some personal learning curves faced when he elected to leave academic life for a new role in a commercial enterprise. View more clips and share your comments at http://ecorner.stanford.edu/authorMaterialInfo.html?mid=2716
Просмотров: 1588 Stanford eCorner
Testosterone and the FDA
Просмотров: 370 BioBalanceHealthcast
Press Briefing on the President's Budget
OMB Director Jack Lew and CEA Chairman Austan Goolsbee give a press briefing on the President's Budget.
Просмотров: 4549 The Obama White House
Typical v. Novel Antipsychotic Side Effects.mp4
Typical v. Novel Antipsychotic Side Effects.mp4
Просмотров: 2665 vpcrashfrog
"Eavesdropping On the Chemical Conversations Between Brain Cells"
A lecture by UM Department of Biomedical and Pharmaceutical Sciences Professor Richard Bridges. This was the first event of the 2011 Community Lecture Series at The University of Montana titled "The Beauty of the Brain." The features six lectures by five outstanding UM faculty members who will examine the science and evolution of learning.
Просмотров: 634 University of Montana
CFSAC November 8, 2011, 9 - 11:15 am
Chronic Fatigue Syndrome Advisory Committee (CFSAC) Meeting, Day 1, November 8, 2011. 9am to 11:15am. Opening Remarks, International Classification of Diseases-Clinical Modification (ICD-CM), and Public Comment
Просмотров: 4207 WomensHealthgov
Supreme Court: The Term in Review (2010-2011), Part 2 of 2
The review of this term's U.S. Supreme Court decisions most likely to affect the work of federal judges will look at opinions deciding First, Fourth, Fifth and Sixth Amendment issues, as well as criminal law, prisoner litigation, sentencing, civil rights, federalism, federal courts, and federal regulations. Our faculty will include Dean Erwin Chemerinsky (University of California -- Irvine, School of Law), Professor Evan Lee (University of California, Hastings College of the Law), Professor Laurie Levenson (Loyola Law School), and Professor Suzanna Sherry (Vanderbilt University Law School). (August 2011)
Просмотров: 1312 United States Courts
El monopolio de la gran industria farmacéutica sobre la propiedad intelectual - TPP
Más información en: http://medicinasparatodos.blogspot.com/ ¿Quién no se ha enfermado alguna vez en su vida? ¿Quién no ha ido a la farmacia y ha tenido que comprar sólo una parte de la receta porque no le alcanza para todo? Esta triste realidad afecta principalmente a las familias más pobres. En la actualidad, la gran industria farmacéutica pretende ampliar su monopolio sobre las patentes de los medicamentos. Esto sería peligroso para el Perú porque si la gran industria farmacéutica consigue ampliar la vigencia del derecho a las patentes o consigue nuevas patentes, uno de los efectos será el aumento de los precios de las medicinas. Es por ello, que en las negociaciones comerciales la propiedad intelectual es un asunto estratégico para la industria farmacéutica. El Perú está recibiendo las presiones de los Estados Unidos y de las industrias farmacéuticas, cuyo poder sigue avanzando de manera peligrosa ¿A quién protegerá el Estado? ¿A los monopolios de las grandes industrias farmacéuticas o a la salud de las peruanas y peruanos? Reportaje y Guión: Ricardo Marapi Cámara: Fernando Salazar Edición: Ricardo Marapi y Fernando Salazar Asistencia de Producción: Mayit Candela Video producido por REDGE y Acción Internacional para la Salud, AIS Más información en: http://medicinasparatodos.blogspot.com/
Просмотров: 19087 Cepes Rural
House Session 2011-02-17 (00:29:22-01:42:59)
Просмотров: 446 CSPANHouse2011
Senate Session 2011-09-08 (11:39:39-12:40:32)
After the transaction of any morning business (not to extend beyond one hour), Senate will continue consideration of H.R. 1249, Leahy-Smith America Invents Act, and at approximately 4 p.m., there will be up to 4 roll call votes on or in relation to Sessions Amendment No. 600, Cantwell Amendment No. 595, Coburn Amendment No. 599, and passage of the bill. Following the Joint Session, Senate will vote on the motion to proceed to consideration of S.J. Res. 25, a joint resolution relating to the disapproval of the President's exercise of authority to increase the debt limit, as submitted under section 3101A of title 31, United States Code, on August 2, 2011.
Просмотров: 129 CSPANSenate2011
Senate Session 2011-10-12 (16:24:41-17:38:10)
Просмотров: 580 CSPANSenate2011
Waste And Abuse: The Refuse Of The Federal Spending Binge (Part 2 of 2)
Waste And Abuse: The Refuse Of The Federal Spending Binge (Part 2 of 2) - House Oversight Committee - HVC 210 - 2011-02-17 - House Committee on Oversight and Government Reform. Thursday's hearing of the House Committee on Oversight and Government Reform, entitled "Waste and Abuse: The Refuse of the Federal Spending Binge," comes during the very week that President Obama presented a .73 trillion budget request to Congress that requires a record .65 trillion in deficit spending, pushes the national debt to surpass GDP for the first time since World War II, and uses budget gimmicks to hide wasteful discretionary spending. Video provided by U.S. House of Representatives.
Просмотров: 9441 HouseResourceOrg
Brunch with Bernie
Thom Hartmann with US Senator Bernie Sanders (I, VT). Weekly town hall meeting If you liked this clip of The Thom Hartmann Program, please do us a big favor and share it with your friends... and hit that "like" button! http://www.thomhartmann.com Follow Us on Twitter: http://www.twitter.com/thom_hartmann Subscribe to The Thom Hartmann Program for more: http://www.youtube.com/subscription_center?add_user=thomhartmann
Просмотров: 462 Thom Hartmann Program